DTIL (Precision BioSciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by DTIL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-05 | Shari Lisa Pire | Director | A | — | — |
| 2026-06-05 | Melinda Brown | Director | A | — | — |
| 2026-06-05 | Stanley Frankel | Director | A | — | — |
| 2026-06-05 | Kevin Buehler | Director | A | — | — |
| 2026-06-05 | Geno J Germano | Director | A | — | — |
| 2026-06-03 | Dario Scimeca | General Counsel and Secretary | A | — | — |
| 2026-06-03 | John Alexander Kelly | Chief Financial Officer | A | — | — |
| 2026-06-03 | Michael Amoroso | President and CEO | A | — | — |
| 2026-06-03 | J. JEFFERSON SMITH | Chief Research Officer | A | — | — |
| 2026-05-22 | Kevin Buehler | Director | M | — | — |
| 2026-05-22 | Stanley Frankel | Director | M | — | — |
| 2026-05-22 | Shari Lisa Pire | Director | M | — | — |
| 2026-05-22 | Geno J Germano | Director | M | — | — |
| 2026-05-22 | Melinda Brown | Director | M | — | — |
| 2026-02-19 | Michael Amoroso | President and CEO | MIXED | — | — |
| 2026-02-19 | Dario Scimeca | General Counsel and Secretary | MIXED | — | — |
| 2026-02-19 | J. JEFFERSON SMITH | Chief Research Officer | MIXED | — | — |
| 2026-02-19 | John Alexander Kelly | Chief Financial Officer | MIXED | — | — |
| 2026-01-22 | Dario Scimeca | General Counsel and Secretary | MIXED | — | — |
| 2026-01-22 | John Alexander Kelly | Chief Financial Officer | MIXED | — | — |
| 2026-01-22 | Michael Amoroso | President and CEO | MIXED | — | — |
| 2026-01-22 | J. JEFFERSON SMITH | Chief Research Officer | MIXED | — | — |
| 2025-12-17 | Stanley Frankel | Director | Buy | — | — |
| 2025-12-17 | Geno J Germano | Director | Buy | — | — |
| 2025-12-17 | Melinda Brown | Director | Buy | — | — |
| 2025-11-04 | John Alexander Kelly | Chief Financial Officer | MIXED | — | — |
| 2025-11-04 | Michael Amoroso | President and CEO | MIXED | — | — |
| 2025-11-04 | Dario Scimeca | General Counsel and Secretary | MIXED | — | — |
| 2025-09-30 | Stanley Frankel | Director | Buy | — | — |
| 2025-09-24 | Melinda Brown | Director | Buy | — | — |
| 2025-07-08 | John Alexander Kelly | Chief Financial Officer | Sell | — | — |
| 2025-06-27 | Kevin Buehler | Director | Buy | — | — |
| 2025-06-27 | Melinda Brown | Director | Buy | — | — |
| 2025-06-04 | Geno J Germano | Director | M | — | — |
| 2025-06-04 | Kevin Buehler | Director | M | — | — |
| 2025-06-04 | Melinda Brown | Director | M | — | — |
| 2025-06-04 | Michael Amoroso | President and CEO | A | — | — |
| 2025-06-04 | Shari Lisa Pire | Director | M | — | — |
| 2025-06-04 | J. JEFFERSON SMITH | Chief Research Officer | A | — | — |
| 2025-06-04 | John Alexander Kelly | Chief Financial Officer | A | — | — |
| 2025-06-04 | Dario Scimeca | General Counsel and Secretary | A | — | — |
| 2025-06-04 | Stanley Frankel | Director | M | — | — |
| 2025-03-28 | Melinda Brown | Director | Buy | — | — |
| 2025-03-28 | Kevin Buehler | Director | Buy | — | — |
| 2025-03-27 | Geno J Germano | Director | Buy | — | — |
| 2025-03-25 | Michael Amoroso | President and CEO | MIXED | — | — |
| 2025-03-05 | Dario Scimeca | General Counsel and Secretary | MIXED | — | — |
| 2025-03-05 | John Alexander Kelly | Chief Financial Officer | M | — | — |
| 2025-03-05 | J. JEFFERSON SMITH | Chief Research Officer | MIXED | — | — |
| 2025-01-22 | Michael Amoroso | President and CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 263,951 | — |
| — | Chief Scientific Officer | 135,801 | — |
| — | Chief Research Officer | 129,857 | — |
| — | Chief Financial Officer | 125,883 | — |
| — | — | 124,608 | — |
| — | President and CEO | 67,803 | — |
| — | General Counsel and Secretary | 61,382 | — |
| — | Director | 49,137 | — |
| — | Director | 44,883 | — |
| — | Director | 44,346 | — |
| — | Director | 40,478 | — |
| — | Director | 35,028 | — |
| — | Director | 5,415 | — |
| — | Chief Financial Officer | 4,813 | — |
| — | Chief Operating Officer | 4,717 | — |
| — | Chief Medical Officer | 4,488 | — |
| — | Director | 4,202 | — |
| — | 10%+ Owner | 1,667 | — |
| — | Director | 1,232 | — |
| — | VP & Corporate Controller | 917 | — |
| — | Chief Medical Officer | 83 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DTIL quote page; the site-wide leaderboard is on the insider transactions hub.